ReviewFrontiers in medicine2026
Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a chronic, heterogeneous disease with marked interindividual variability in response to anti-obesity medications. Although GLP-1 receptor agonists (GLP-1RAs) and dual incretin agonists produce substantial average weight loss in clinical trials, real-world effectiveness is limited by interindividual variability, gastrointestinal intolerance, incomplete dose escalation, cost and access barriers, poor long-term persistence, and weight plateau or regain in a subset of treated patients. Weight regain is particularly consistent after treatment discontinuation, reinforcing the chronic-care nature of obesity pharmacotherapy. Objective: To synthesize evidence on phenotypic and genomic determinants of variability in pharmacotherapy response and propose a pragmatic framework for precision pharmacotherapy in obesity. Methods: Narrative review integrating data from randomized trials, Results: Response heterogeneity reflects interactions among central satiety and reward circuitry, baseline metabolic and glycemic status, sex, baseline adiposity, treatment indication, previous GLP-1RA exposure, adherence, and tolerability. Early on-treatment weight change, usually assessed within 12-16 weeks and in some liraglutide studies as early as 1 month, is the most clinically actionable predictor of longer-term outcomes. Phenotype-guided approaches that classify dominant mechanisms such as impaired satiation, postprandial hunger, emotional or hedonic eating, and low energy expenditure offer a feasible bridge between pathophysiology and medication selection. Emerging genomic signals are promising but remain insufficiently replicated for routine clinical use. Conclusion: Precision pharmacotherapy in obesity is most viable today through phenotype-guided treatment, structured early-response monitoring, and proactive management of adherence and tolerability. Genomic tools may eventually refine treatment selection, but they remain investigational and require prospective, multi-ancestry validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.